Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN) | Synapse
July 16, 2020Open Access
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
Key Points
Key points are not available for this paper at this time.
Abstract
Sorafenib maintenance therapy reduces the risk of relapse and death after HCT for FLT3-ITD-positive AML.